What is RIGL's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.92B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for RIGL?

P/E (TTM) is 2.85 and 52-week range is $24.95 to $52.24 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s RIGL figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for RIGL?

The company profile lists revenue (TTM) near $262M, net income (TTM) near $304M, EPS (TTM) near $16.04 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Rigel Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in South San Francisco, California, US, 18.5M shares outstanding, ISIN US7665597024 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Rigel Pharmaceuticals Inc

$RIGL

Health Care · Biotechnology

IR Run Scenarios

$49.08

+0.74%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company is headquartered in South San Francisco, California and currently employs 172 full-time employees. The company went IPO on 2000-11-29. The firm is engaged in developing and providing therapies for patients with hematologic disorders and cancer. The company focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. The company is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.

Employees

173

Website

www.rigel.com/

IPO

2000-11-29

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)